keyword
MENU ▼
Read by QxMD icon Read
search

Who ovarian cancer

keyword
https://www.readbyqxmd.com/read/28223670/-clinical-management-of-hboc-in-our-hospital
#1
Hidetaka Nomura, Nobuhiro Takeshima
The cumulative risks of developing epithelial ovarian cancer in women aged 70-75years with BRCA1 and BRCA2 germline mutations are approximately 39-40% and 11-18%, respectively. Here, we present the management of hereditary breast and ovarian cancer(HBOC)in our hospital. HBOC management commences with the selection of appropriate candidates for genetic testing, based on personal and familial characteristics that determine the individual's probability of being a mutation carrier. Pre-test counseling, which is an essential element of genetic counseling, should include discussion of why the test is being offered, how the test results may affect medical management, and the cancer risks associated with the gene mutation...
February 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28222899/is-the-neutrophil-to-lymphocyte-ratio-prognostic-of-survival-outcomes-in-gynecologic-cancers-a-systematic-review-and-meta-analysis
#2
REVIEW
Josee-Lyne Ethier, Danielle N Desautels, Arnoud J Templeton, Amit Oza, Eitan Amir, Stephanie Lheureux
BACKGROUND: Presence of a high neutrophil-to-lymphocyte ratio (NLR) has been associated with increased mortality in several malignancies. Here, we quantify the effect of NLR on survival in patients with gynecologic cancers, and examine the effect of clinico-pathologic factors on its prognostic value. METHODS: A systematic search of electronic databases was conducted to identify publications exploring the association of pre-treatment blood NLR with overall survival (OS) and event-free survival (EFS) among patients with ovarian, endometrial and cervical cancers...
February 17, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28221868/somatic-brca1-2-recovery-as-a-resistance-mechanism-after-exceptional-response-to-poly-adp-ribose-polymerase-inhibition
#3
Stephanie Lheureux, Jeff P Bruce, Julia V Burnier, Katherine Karakasis, Patricia A Shaw, Blaise A Clarke, S Y Cindy Yang, Rene Quevedo, Tiantian Li, Mark Dowar, Valerie Bowering, Trevor J Pugh, Amit M Oza
Purpose Durable and long-term responses to the poly (ADP-ribose) polymerase inhibitor olaparib are observed in patients without BRCA1/2 mutations. However, beyond BRCA1/2 mutations, there are no approved biomarkers for olaparib in high-grade serous ovarian cancer (HGSOC). To determine mechanisms of durable response and resistance to olaparib therapy, we performed an analysis of HGSOC tumors from three patients without germline BRCA1/2 mutations who experienced exceptional responses to olaparib. Patients and Methods We performed integrated exome, low-pass genome, and RNA sequence analysis of tumors at diagnosis and upon relapse from patients with platinum-sensitive HGSOC recurrence who were treated > 5 years with olaparib therapy as a single agent...
February 21, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28215816/nasal-septal-perforation-secondary-to-systemic-bevacizumab
#4
Mathew Geltzeiler, Toby O Steele
IMPORTANCE: A case of nasal septal perforation secondary to systemic bevacizumab therapy for ovarian cancer is reported. Bevacizumab is a vascular endothelial growth factor A (VEGF-A) inhibitor that is becoming more widely utilized in the oncologic community. There is only one prior report of septal perforation secondary to bevacizumab in the Otolaryngology specific literature. The purpose of this report is: 1) to raise awareness and discuss the literature surrounding the sinonasal complications of bevacizumab and 2) provide workup and treatment recommendations based on the sum of the available literature...
January 19, 2017: American Journal of Otolaryngology
https://www.readbyqxmd.com/read/28211638/the-relationship-between-ovarian-function-and-ovarian-limited-dose-in-radiotherapy-postoperation-of-ovarian-transposition-in-young-patients-with-cervical-cancer
#5
Zhenhua Du, Hui Qu
In this study, the relationship between ovarian function and ovarian limited dose in radiotherapy was evaluated in young patients with cervical cancer who underwent ovarian transposition (Fig1B). Moreover, the novel ovarian dose limit for a better preservation of ovarian function in intensity-modulated radiation therapy (IMRT) was determined. We retrospectively analyzed data from 86 patients with cervical cancer who received radical hysterectomy and ovarian transposition from January 2013 to June 2015. In agreement with the National Comprehensive Cancer Network Guidelines (NCCN) for Cervical Cancer Version 2...
February 17, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28209595/prediagnosis-leukocyte-telomere-length-and-risk-of-ovarian-cancer
#6
Meng Yang, Jennifer Prescott, Elizabeth M Poole, Megan S Rice, Laura D Kubzansky, Annika Idahl, Eva Lundin, Immaculata De Vivo, Shelley S Tworoger
Background: The associations between telomere length and cancer risk are equivocal, and none have examined the association between prediagnosis leukocyte telomere length (LTL) and the risk of developing ovarian cancer.Methods: We prospectively measured LTL collected from 442 ovarian cancer cases and 727 controls in the Nurses' Health Studies and the Northern Sweden Health and Disease Study. Cases were matched to one or two controls on age, menopausal status, and date of blood collection. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using conditional logistic regression...
February 16, 2017: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/28209497/a-multicenter-assessment-of-the-ability-of-preoperative-computed-tomography-scan-and-ca-125-to-predict-gross-residual-disease-at-primary-debulking-for-advanced-epithelial-ovarian-cancer
#7
Rudy S Suidan, Pedro T Ramirez, Debra M Sarasohn, Jerrold B Teitcher, Revathy B Iyer, Qin Zhou, Alexia Iasonos, John Denesopolis, Oliver Zivanovic, Kara C Long Roche, Yukio Sonoda, Robert L Coleman, Nadeem R Abu-Rustum, Hedvig Hricak, Dennis S Chi
OBJECTIVE: To assess the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease (RD) at primary cytoreduction in advanced ovarian cancer. METHODS: A prospective, non-randomized, multicenter trial of patients who underwent primary debulking for stage III-IV epithelial ovarian cancer previously identified 9 criteria associated with suboptimal (>1cm residual) cytoreduction. This is a secondary post-hoc analysis looking at the ability to predict any RD...
February 13, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28205045/characteristics-of-brca1-2-mutations-carriers-including-large-genomic-rearrangements-in-high-risk-breast-cancer-patients
#8
Boyoung Park, Ji Yeon Sohn, Kyong-Ah Yoon, Keun Seok Lee, Eun Hae Cho, Myong Cheol Lim, Moon Jung Yang, Soo Jin Park, Moo Hyun Lee, See Youn Lee, Yoon Jung Chang, Dong Ock Lee, Sun-Young Kong, Eun Sook Lee
PURPOSE: We investigated the prevalence of BRCA1/2 small mutations and large genomic rearrangements in high risk breast cancer patients who attended a genetic counseling clinic. METHODS: In total 478 patients were assessed for BRCA1/2 mutations by direct sequencing, of whom, 306 were identified as non-carriers of BRCA1/2 mutation and assessed for large rearrangement mutations by multiplex ligation-dependent probe amplification. Family history and clinicopathological characteristics of patients were evaluated...
February 15, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28202637/supplemental-selenium-may-decrease-ovarian-cancer-risk-in-african-american-women
#9
Paul D Terry, Bo Qin, Fabian Camacho, Patricia G Moorman, Anthony J Alberg, Jill S Barnholtz-Sloan, Melissa Bondy, Michele L Cote, Ellen Funkhouser, Kristin A Guertin, Edward S Peters, Ann G Schwartz, Joellen M Schildkraut, Elisa V Bandera
Background: To our knowledge, no previous study has evaluated the associations of antioxidant intake with the risk of ovarian cancer in African-American women, who are known to have high mortality from the disease.Objective: We sought to evaluate these associations among 406 ovarian cancer cases and 632 age- and site-matched controls of African-American descent recruited from AACES (African American Cancer Epidemiology Study), a population-based, case-control study in 11 geographical areas within the United States...
February 15, 2017: Journal of Nutrition
https://www.readbyqxmd.com/read/28202195/long-term-ototoxicity-in-women-after-cisplatin-treatment-for-ovarian-germ-cell-cancer
#10
Jakob Skalleberg, Olesya Solheim, Sophie D Fosså, Milada Cvancarova Småstuen, Terje Osnes, Per Ole M Gundersen, Marie Bunne
OBJECTIVE: Evaluate long-term cisplatin-induced ototoxicity in women treated for malignant ovarian germ cell tumors (MOGCT). METHODS: Seventy-four women treated for MOGCT in Norway (1980-2009) were analyzed: 41 had received cisplatin-based chemotherapy (CBCT) ("Cases") and 33 had no CBCT ("Controls"). Median follow-up was 15years. Hearing was assessed by pure tone audiometry and by the SCIN questionnaire. Air conduction thresholds were reported as absolute hearing thresholds and age-adjusted thresholds...
February 12, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28198358/combination-of-aprepitant-azasetron-and-dexamethasone-as-antiemetic-prophylaxis-in-women-with-gynecologic-cancers-receiving-paclitaxel-carboplatin-therapy
#11
Masafumi Koshiyama, Noriomi Matsumura, Saeko Imai, Koji Yamanoi, Kaoru Abiko, Yumiko Yoshioka, Ken Yamaguchi, Junzo Hamanishi, Tsukasa Baba, Ikuo Konishi
BACKGROUND The aim of this study was to evaluate the antiemetic effect of aprepitant and to determine how to provide triple combination therapy (aprepitant/azasetron/dexamethasone) to women receiving paclitaxel/carboplatin moderately emetogenic chemotherapy (MEC). MATERIAL AND METHODS The current study was a prospective study of 163 women with gynecologic cancers. We compared the digestive symptoms scores (nausea, vomiting, appetite loss, and dietary intake) of 37 women with ovarian cancers before and after aprepitant administration...
February 15, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/28197806/recruiting-families-at-risk-for-hereditary-breast-and-ovarian-cancer-from-a-statewide-cancer-registry-a-methodological-study
#12
Maria C Katapodi, Deb Duquette, James J Yang, Kari Mendelsohn-Victor, Beth Anderson, Christos Nikolaidis, Emily Mancewicz, Laurel L Northouse, Sonia Duffy, David Ronis, Kara J Milliron, Nicole Probst-Herbst, Sofia D Merajver, Nancy K Janz, Glenn Copeland, Scott Roberts
PURPOSE: Cancer genetic services (counseling/testing) are recommended for women diagnosed with breast cancer younger than 45 years old (young breast cancer survivors-YBCS) and at-risk relatives. We present recruitment of YBCS, identification and recruitment of at-risk relatives, and YBCS willingness to contact their cancer-free, female relatives. METHODS: A random sample of 3,000 YBCS, stratified by race (Black vs. White/Other), was identified through a population-based cancer registry and recruited in a randomized trial designed to increase use of cancer genetic services...
February 14, 2017: Cancer Causes & Control: CCC
https://www.readbyqxmd.com/read/28196146/chemotherapy-induces-adaptive-drug-resistance-and-metastatic-potentials-via-phenotypic-cxcr4-expressing-cell-state-transition-in-ovarian-cancer
#13
Hyun Hee Lee, Vanessa Bellat, Benedict Law
Ovarian cancer (OVC) patients who receive chemotherapy often acquire drug resistance within one year. This can lead to tumor reoccurrence and metastasis, the major causes of mortality. We report a transient increase of a small distinctive CXCR4High/CD24Low cancer stem cell population (CXCR4High) in A2780 and SKOV-3 OVC cell lines in response to cisplatin, doxorubicin, and paclitaxel, treatments. The withdrawal of the drug challenges reversed this cell-state transition. CXCR4High exhibits dormancy in drug resistance and mesenchymal-like invasion, migration, colonization, and tumor formation properties...
2017: PloS One
https://www.readbyqxmd.com/read/28188963/high-risk-epithelial-ovarian-cancer-patients-for-hereditary-ovarian-cancer
#14
Seksit Chirasophon, Tarinee Manchana, Chinachote Teerapakpinyo
AIM: Risk assessment to identify patients at risk for hereditary ovarian cancer is important. The objectives of this study were to evaluate the frequency of high-risk epithelial ovarian cancer (EOC) patients and the frequency of germline mutation in these patients. METHODS: A total of 335 patients with histologically confirmed non-mucinous EOC were included. High-risk patients were defined as patients who had: (i) significant family history of breast/ovarian/colorectal/endometrial cancers; (ii) synchronous breast/endometrial/colorectal cancer; or (iii) high-grade serous carcinoma...
February 11, 2017: Journal of Obstetrics and Gynaecology Research
https://www.readbyqxmd.com/read/28188769/lifetime-cancer-risk-and-combined-oral-contraceptives-the-royal-college-of-general-practitioners-oral-contraception-study
#15
Lisa Iversen, Selvaraj Sivasubramaniam, Amanda J Lee, Shona Fielding, Philip C Hannaford
BACKGROUND: Oral contraceptives have been used by hundreds of millions of women around the world. Important questions remain regarding the very long-term cancer risks associated with oral contraception. Despite previous research important questions remain about the safety of these contraceptives: i) how long do endometrial, ovarian and colorectal cancer benefits persist for? ii) does combined oral contraceptive use during the reproductive years produce new cancer risks later in life? and iii) what is the overall balance of cancer among past users as they enter the later stages of their lives? OBJECTIVES: To examine the very long-term cancer risks or benefits associated with use of combined oral contraceptives, including the estimated overall life-time balance...
February 8, 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28187099/serous-tubal-intraepithelial-carcinoma-associated-with-extraovarian-metastases
#16
Stephanie Schneider, Sebastian Heikaus, Philipp Harter, Florian Heitz, Christoph Grimm, Beyhan Ataseven, Sonia Prader, Christian Kurzeder, Thomas Ebel, Alexander Traut, Andreas du Bois
OBJECTIVE: The evolving knowledge of ovarian carcinogenesis sets the stage for our understanding of high-grade serous pelvic carcinoma (HGSC). Findings in prophylactic surgery introduced serous tubal intraepithelial carcinoma (STIC) as potential precursor of HGSC. The present study explores whether STIC instead should already be considered as an early stage of HGSC with a need for comprehensive staging and therapy. PATIENTS AND METHODS: We identified all consecutive patients with HGSC who received first-line therapy in our referral center for gynecologic oncology from January 2011 to April 2016...
March 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28187098/preoperative-predictive-factors-for-complete-cytoreduction-and-survival-outcome-in-epithelial-ovarian-tubal-and-peritoneal-cancer-after-neoadjuvant-chemotherapy
#17
Min-Hyun Baek, Shin-Wha Lee, Jeong-Yeol Park, Chae Chun Rhim, Dae-Yeon Kim, Dae-Shik Suh, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, Joo-Hyun Nam
OBJECTIVE: The study aims to identify preoperative predictors of complete cytoreduction and early recurrence and death in epithelial ovarian, tubal, and peritoneal cancer after neoadjuvant chemotherapy (NACT). METHODS: We performed a retrospective analysis of 85 patients who underwent 3 cycles of NACT. Patients were divided into 2 groups according to residual tumor at interval debulking surgery (IDS), and clinicopathologic, surgical, and follow-up data were compared...
March 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28187092/incidence-of-venous-thromboembolism-by-type-of-gynecologic-malignancy-and-surgical-modality-in-the-national-surgical-quality-improvement-program
#18
Ashley Graul, Nawar Latif, Xiaochen Zhang, Lorraine T Dean, Mark Morgan, Robert Giuntoli, Robert Burger, Sarah Kim, Emily Ko
BACKGROUND: Women with gynecologic cancer are at higher risk of venous thromboembolism (VTE) due to malignancy, pelvic surgery, increased age, and frequently comorbidities. The rate of VTE among different gynecologic cancers and relative to benign gynecologic surgeries has not been reported in a nationally representative cohort. METHODS: Using the American College of Surgeons National Surgical Quality Improvement Program database, gynecologic surgeries were identified retrospectively from 2006 to 2012...
March 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28187090/impact-of-conservative-managements-in-young-women-with-grade-2-or-3-endometrial-adenocarcinoma-confined-to-the-endometrium
#19
Clementine Gonthier, Alice Trefoux-Bourdet, Martin Koskas
OBJECTIVES: The aim of this study was to evaluate the impact of ovarian and/or uterine preservation in young patients with grade 2 or 3 endometrial adenocarcinoma confined to the endometrium. METHODS/MATERIALS: A population-based analysis was conducted. The SEER'17 Database was used to identify women younger than 45 years with grade 2 or 3 endometrial adenocarcinoma confined to the endometrium from 1983 to 2012. A cohort of 1106 women was included: 849 underwent hysterectomy with bilateral adnexectomy, 96 underwent hysterectomy with ovarian preservation, and 49 underwent uterine preservation...
March 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28185173/ovarian-function-suppression-in-premenopausal-women-with-early-stage-breast-cancer
#20
REVIEW
Matteo Lambertini, Lucia Del Mastro, Giulia Viglietti, Noam F Pondé, Cinzia Solinas, Evandro de Azambuja
Breast cancers arising in young women are biologically more aggressive, and most of these patients are candidates to receive aggressive treatments that include the use of chemotherapy. As most of these tumors express the hormone receptors (i.e., luminal disease), these patients are also candidates to adjuvant endocrine therapy. Chemotherapy-induced amenorrhea showed to be prognostic in young patients with luminal breast cancer. However, the role of ovarian function suppression (OFS) in addition to standard adjuvant treatments has been largely debated over the past years...
January 2017: Current Treatment Options in Oncology
keyword
keyword
100582
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"